128 related articles for article (PubMed ID: 1682994)
1. Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Kobayashi T; Furuta S; Kanai M
Scand J Gastroenterol; 1991 Sep; 26(9):981-92. PubMed ID: 1682994
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2.
Kawa S; Kato M; Oguchi H; Hsue GL; Kobayashi T; Koiwai T; Tokoo M; Furuta S; Ichikawa T; Kanai M
Scand J Gastroenterol; 1992 Aug; 27(8):635-43. PubMed ID: 1359630
[TBL] [Abstract][Full Text] [Related]
3. Preparation and partial characterization of a pancreatic cancer-associated glycoprotein expressing CA50.
Kawa S; Kato M; Oguchi H; Kobayashi T; Hsue GL; Koiwai T; Aoki Y; Furuta S; Kanai M
Scand J Gastroenterol; 1991 Dec; 26(12):1307-18. PubMed ID: 1662409
[TBL] [Abstract][Full Text] [Related]
4. Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin.
Ho JJ; Bi N; Yan PS; Yuan M; Norton KA; Kim YS
Cancer Res; 1991 Jan; 51(1):372-80. PubMed ID: 1703039
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
Kawa S; Oguchi H; Kobayashi T; Tokoo M; Furuta S; Kanai M; Homma T
Br J Cancer; 1991 Nov; 64(5):899-902. PubMed ID: 1931612
[TBL] [Abstract][Full Text] [Related]
6. Epitope analysis of SPan-1 and DUPAN-2 using synthesized glycoconjugates sialyllact-N-fucopentaose II and sialyllact-N-tetraose.
Kawa S; Tokoo M; Oguchi H; Furuta S; Homma T; Hasegawa Y; Ogata H; Sakata K
Pancreas; 1994 Nov; 9(6):692-7. PubMed ID: 7531332
[TBL] [Abstract][Full Text] [Related]
7. Expression of glycoconjugates in pancreatic, gastric, and colonic tissue by Bauhinia purpurea, Vicia villosa, and peanut lectins.
Shue GL; Kawa S; Kato M; Oguchi H; Kobayashi T; Koiwai T; Tokoo M; Furuta S; Kanai M; Homma T
Scand J Gastroenterol; 1993 Jul; 28(7):599-604. PubMed ID: 8362212
[TBL] [Abstract][Full Text] [Related]
8. Expression of CA19-9, DU-PAN-2, and SPan-1 antigens on two types of normal salivary mucins.
Ho JJ; Norton K; Chung YS; Kim YS
Oncol Res; 1993; 5(9):347-56. PubMed ID: 7518709
[TBL] [Abstract][Full Text] [Related]
9. Purification and characterization of a peanut-agglutinin-binding pancreatic-cancer-related serum mucus glycoprotein.
Ching CK; Rhodes JM
Int J Cancer; 1990 Jun; 45(6):1022-7. PubMed ID: 2351483
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer.
Hanski C; Hanski ML; Zimmer T; Ogorek D; Devine P; Riecken EO
Cancer Res; 1995 Feb; 55(4):928-33. PubMed ID: 7850810
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of X-hapten-like antigen and antigen YH206 on mucin molecules.
Hinoda Y; Imai K; Ban T; Itoh F; Yachi A
Gastroenterol Jpn; 1991 Feb; 26(1):56-61. PubMed ID: 1706671
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
14. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
[TBL] [Abstract][Full Text] [Related]
15. Expression of various sialylated carbohydrate antigens in malignant and nonmalignant pancreatic tissues.
Satomura Y; Sawabu N; Takemori Y; Ohta H; Watanabe H; Okai T; Watanabe K; Matsuno H; Konishi F
Pancreas; 1991 Jul; 6(4):448-58. PubMed ID: 1678888
[TBL] [Abstract][Full Text] [Related]
16. Quantitative and qualitative characterization of human cancer-associated serum glycoprotein antigens expressing epitopes consisting of sialyl or sialyl-fucosyl type 1 chain.
Kannagi R; Kitahara A; Itai S; Zenita K; Shigeta K; Tachikawa T; Noda A; Hirano H; Abe M; Shin S
Cancer Res; 1988 Jul; 48(13):3856-63. PubMed ID: 2454154
[TBL] [Abstract][Full Text] [Related]
17. Identification and partial characterization of a new pancreatic cancer-related serum glycoprotein by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and lectin blotting.
Ching CK; Rhodes JM
Gastroenterology; 1988 Jul; 95(1):137-42. PubMed ID: 3163659
[TBL] [Abstract][Full Text] [Related]
18. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of CA-50 (time-resolved fluoroimmunoassay), Span-1, and CA19-9 in the diagnosis of pancreatic cancer.
Kobayashi T; Kawa S; Tokoo M; Oguchi H; Kiyosawa K; Furuta S; Kanai M; Homma T
Scand J Gastroenterol; 1991 Jul; 26(7):787-97. PubMed ID: 1896821
[TBL] [Abstract][Full Text] [Related]
20. Serum concentration and immunohistochemical localization of SPan-1 antigen in pancreatic cancer. A comparison with CA19-9 antigen.
Takeda S; Nakao A; Ichihara T; Suzuki Y; Nonami T; Harada A; Koshikawa T; Takagi H
Hepatogastroenterology; 1991 Apr; 38(2):143-8. PubMed ID: 1855772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
